Lexaria Bioscience Corp. LXX Archives

WednesdaySep 09, 2020 11:53 am

QualityStocksNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Secures C$13.29M Through Previously Announced Offering

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today confirmed that it has closed its previously announced offering of units for aggregate gross proceeds of approximately C$13.29 million. According to the update, the company issued 15,640,000 units, each at a price of C$0.85, with each unit consisting of one common share of the company and ½ of one common share purchase warrant, with each whole warrant entitling the holder to purchase one share, at the price of C$1.10 per share, until September 9, 2023. “Over the last four years, LexaGene…

FridayAug 03, 2018 1:55 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enabling Companies to Produce High-Quality Cannabis-Infused Products

80 percent of the company’s total revenue anticipated from the licensing of DehydraTECH™ Nuke Enterprises renewed its license, sending a strong vote of confidence in the technology Enabled GP Holdings to create a high-performing cannabis-infused beverage Biolog Inc. is developing products which will allow processors and consumers to turn almost any food or beverage into a cannabis edible Beginning production of a line of cannabis-infused alcohol-free beverages through a new licensing agreement Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, utilizes its unique patented DehydraTECH™ delivery technology to enhance the products of its clients. This patented…

TuesdayJun 19, 2018 11:43 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Ending the Need to Light-Up

Lexaria is ahead of the game in the expected second flow of investment capital in “plant-to-bloodstream” companies Company’s DehydraTECH™ technology has the potential to revolutionize nicotine use, eliminating the major cause of related deaths by shifting demand away from smoking cigarettes DehydraTECH™ makes it possible to experience most of the positives associated with inhalation while eliminating the negatives, helping to make lighting up a thing of the past Within the cannabis industry, the initial flow of investment capital has been toward ‘seed-to-plant’ companies. As the next stage of investment is expected to be ‘plant-to-bloodstream’, companies such as Lexaria Bioscience Corp.…

ThursdayJun 14, 2018 1:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appeals to Investors with Slow Burn Rate, Model that Goes Beyond Cannabis Sector

Chris Bunka, CEO of LXRP, in an interview with CFN Media Group, stated that his company’s cash flow is strengthening from licensing and R&D, with technology applicable to other sectors Bunka noted that LXRP’s 71 million share count is kept purposely low relative to others in the category, with its valuation growing by “close to 2,000 percent” over the past several years LXRP’s goal is to slow disease and make cannabis acceptable to the general population Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in…

WednesdayJun 13, 2018 12:06 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on Delivery of Bioactive Substances via Oral Ingestion

Lexaria has its patented DehydraTECH™ nutrient infusion technology This technology has patent protection for cannabidiol and all other non-psychoactive cannabinoids DehydraTECH™ technology provides greater bio-absorption Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a worldwide leader in enhancing the gastro-intestinal delivery of edible cannabinoid products. The company has its patented nutrient infusion technology called DehydraTECH™. This technology significantly improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other beneficial molecules. Lexaria Bioscience is headquartered in Kelowna, British Columbia. Lexaria has patents granted in the United States and Australia for applications of its…

TuesdayJun 05, 2018 11:28 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Patent Portfolio, Announces Exercise of 450,000 Existing Warrants

LXRP, a drug delivery platform innovator, has been awarded two new patent grants in the U.S. and expects three more from Australia Company already has more than 40 patent awards or applications from 40 countries globally; it is preparing new patent application filings and predicts more patent awards this year LXRP received $63,000 from the exercise of 450,000 warrants previously granted to third parties Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is growing its patent portfolio with two more patent grants in the U.S., predicting three more from Australia, and it is currently preparing new patent application filings as it…

WednesdayMay 23, 2018 12:07 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Boosts Prospects for Smoke-Free Nicotine Future

New FDA restrictions on Big Tobacco take effect Tobacco manufacturers turning to ‘reduced-risk’ products No edible nicotine products currently available DehydraTECH improves bio-absorption of nicotine taken orally Smoking may be a dying trend, but consumption of nicotine is not only very much alive; its longevity is assured by Big Tobacco’s foray into alternative tobacco and ‘reduced-risk’ products. Driven by increased public awareness and government policy, the pressure has been turned up on smokers to quit, and cigarette manufacturers are feeling the heat, as well. New regulations mandating warnings against the adverse health effects of smoking and the addictive power of…

WednesdayMay 16, 2018 12:23 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strategically Disrupting Drug Delivery

Expanding the applicability of edible delivery technology within the drug industry Creating strategic partnerships through licensing agreements Breakthrough in nicotine absorption study supports further investigation into the many possible uses beyond the cannabis and nicotine industries Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, partners with leading companies within the drug industry. The company is known primarily for removing objectionable flavors while improving the effectiveness of gastro-intestinal delivery of edible cannabinoid consumer products, but the company is now working to expand the applicability of its technology beyond the cannabis industry. DehydraTECH™ is Lexaria’s edible delivery technology…

MondayMay 14, 2018 1:24 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Licensing Agreement Renewal with Nuka Enterprises Reinforces DehydraTECH™ Revenue Strategy

Report: LXRP is a ‘compelling investment opportunity’ which is creating recurring licensing revenue that unlocks shareholder value LXRP’s DehydraTECH is a patented delivery technology platform that is renewal-licensed by Nuka in a 10-year semi-exclusive agreement that expands its reach into Canada Company is growing its patent portfolio for proprietary DehydraTECH; it already has patents granted in Australia and the U.S. and has patents pending in more than 40 countries worldwide Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) renewal of its DehydraTECH™ license with Nuka Enterprises LLC could help make it a compelling investment opportunity in the cannabis industry as its…

TuesdayApr 24, 2018 12:23 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Human Clinical Study of Its High Absorption TurboCBD Capsules

Study will measure the cardiovascular and cognitive health effects of patented DehydraTECH, its disruptive delivery technology Data generated will help company’s development of next-generation cannabinoid product formulations Chris Bunka, CEO, and John Docherty, president, to present at the ‘Next Generation Nicotine Delivery USA 2018’ conference in Atlanta on April 24 and 25 Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has started a human clinical study in Europe on the health effects of its high absorption TurboCBD™ capsules. LXRP, a drug delivery platform innovator, will be conducting the study to evaluate the cardiovascular and cognitive health effects of its patented DehydraTECH™…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXX